Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4.8% - Should You Sell?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report)'s share price dropped 4.8% during mid-day trading on Monday . The stock traded as low as $6.71 and last traded at $6.72. Approximately 256,819 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,323,244 shares. The stock had previously closed at $7.06.

Analyst Ratings Changes

TRVI has been the subject of several recent analyst reports. B. Riley restated a "buy" rating and issued a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. D. Boral Capital reiterated a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, June 2nd. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, May 20th. HC Wainwright began coverage on Trevi Therapeutics in a report on Wednesday, May 28th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $18.63.

Trevi Therapeutics Stock Down 1.3%

The stock has a 50 day simple moving average of $6.27 and a two-hundred day simple moving average of $5.06. The stock has a market capitalization of $616.34 million, a P/E ratio of -14.02 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. Sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Transactions at Trevi Therapeutics

In related news, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 18.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its position in shares of Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. acquired a new position in Trevi Therapeutics in the 4th quarter worth about $49,000. Strs Ohio acquired a new position in Trevi Therapeutics in the 1st quarter worth about $52,000. Squarepoint Ops LLC acquired a new position in Trevi Therapeutics in the 4th quarter worth about $58,000. Finally, Two Sigma Advisers LP acquired a new position in Trevi Therapeutics in the 4th quarter worth about $66,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.